公开(公告)号：US20240300891A1

公开(公告)日：2024-09-12

申请号：US18578361

申请日：2022-09-07

Applicant: University of Cincinnati

Inventor： Joo-Youp Lee ,  Vishnu Sriram

IPC: C07D211/62 ,  A61K47/54 ,  A61K47/69

CPC classification number: C07D211/62 ,  A61K47/543 ,  A61K47/6929

Abstract: A composition including ionizable lipids is provided. Also provided is a composition forming lipid nanoparticle, wherein the composition includes the ionizable lipid, a helper lipid, a sterol, and a PEGylated lipid conjugate. Also provided are methods of making the ionizable lipids. The ionizable lipids can include 2AEOAP2, 2AEOAP4, 2AELAP2, 2AELAP4, Lipid 16A, Lipid 16B, Lipid 16C, Lipid 16B, and Lipid 20B.

公开(公告)号：US12077483B2

公开(公告)日：2024-09-03

申请号：US17299925

申请日：2019-12-05

Applicant: Intellia Therapeutics, Inc.

Inventor： Stephen S. Scully ,  Micah Maetani ,  Ramsey Majzoub

IPC: C07C219/04 ,  A61P1/16 ,  C07C271/20 ,  C07D205/04 ,  C07D207/09 ,  C07D211/46 ,  C07D211/62 ,  C07D271/10 ,  C07D295/08 ,  C12N15/113 ,  B82Y5/00 ,  B82Y30/00 ,  B82Y40/00

CPC classification number: C07C219/04 ,  A61P1/16 ,  C07C271/20 ,  C07D205/04 ,  C07D207/09 ,  C07D211/46 ,  C07D211/62 ,  C07D271/10 ,  C07D295/08 ,  C12N15/113 ,  B82Y5/00 ,  B82Y30/00 ,  B82Y40/00 ,  C12N2310/315 ,  C12N2310/321

Abstract: The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The ionizable amine lipids disclosed herein are useful as ionizable lipids in the formulation of lipid nanoparticle-based compositions.

公开(公告)号：US11851449B2

公开(公告)日：2023-12-26

申请号：US17316185

申请日：2021-05-10

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Satoshi Yamamoto ,  Junya Shirai ,  Mitsunori Kono ,  Yoshihide Tomata ,  Ayumu Sato ,  Atsuko Ochida ,  Yoshiyuki Fukase ,  Shoji Fukumoto ,  Tsuneo Oda ,  Hidekazu Tokuhara ,  Naoki Ishii ,  Yusuke Sasaki

IPC: C07F7/08 ,  C07D205/04 ,  C07D207/12 ,  C07K5/065 ,  C07D239/36 ,  C07D213/64 ,  C07D309/06 ,  C07D333/38 ,  C07F7/10 ,  C07D403/06 ,  C07D271/10 ,  C07C237/22 ,  C07D295/14 ,  C07D207/26 ,  C07D413/12 ,  C07F7/30 ,  C07D233/72 ,  C07D309/08 ,  C07D231/56 ,  C07D261/08 ,  C07D209/18 ,  C07D405/12 ,  C07D261/12 ,  C07D239/54 ,  C07D211/62 ,  C07D237/14 ,  C07D231/12 ,  C07D487/04 ,  A61P43/00 ,  A61P29/00 ,  A61P25/00 ,  A61P19/02 ,  A61P17/06 ,  A61P1/04 ,  C07K5/087

CPC classification number: C07F7/0812 ,  A61P1/04 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P29/00 ,  A61P43/00 ,  C07C237/22 ,  C07D205/04 ,  C07D207/12 ,  C07D207/26 ,  C07D209/18 ,  C07D211/62 ,  C07D213/64 ,  C07D231/12 ,  C07D231/56 ,  C07D233/72 ,  C07D237/14 ,  C07D239/36 ,  C07D239/54 ,  C07D261/08 ,  C07D261/12 ,  C07D271/10 ,  C07D295/14 ,  C07D309/06 ,  C07D309/08 ,  C07D333/38 ,  C07D403/06 ,  C07D405/12 ,  C07D413/12 ,  C07D487/04 ,  C07F7/081 ,  C07F7/10 ,  C07F7/30 ,  C07K5/06078 ,  C07K5/0812

Abstract: The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.

公开(公告)号：US20230373919A1

公开(公告)日：2023-11-23

申请号：US18315533

申请日：2023-05-11

Applicant: Eli Lilly and Company

Inventor： Thomas James BEAUCHAMP ,  Zhaogen CHEN ,  Scott Eugene CONNER ,  Jon Andre ERICKSON ,  Maria Cristina GARCIA PAREDES ,  Jayana Pankajkumar LINESWALA ,  Emanuele SHER ,  Bishnu THAPA ,  Leonard Larry WINNEROSKI, II

IPC: C07D211/62 ,  C07D405/12 ,  C07D401/06 ,  C07D401/04 ,  C07D471/04 ,  C07D405/14

CPC classification number: C07D211/62 ,  C07D405/12 ,  C07D401/06 ,  C07D401/04 ,  C07D471/04 ,  C07D405/14

Abstract: This invention provides certain piperidine compounds as AT2R antagonists, e.g., compounds of formula (I):






or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and X are as defined herein, pharmaceutical compositions thereof, and methods of using the same to treat pain associated with AT2R activity.

公开(公告)号：US20230339851A1

公开(公告)日：2023-10-26

申请号：US18186265

申请日：2023-03-20

Applicant: CHEMOCENTRYX, INC.

Inventor： Hiufung CHU ,  Pingchen FAN ,  Yandong LI ,  Viengkham MALATHONG ,  Jay POWERS ,  Hiroko TANAKA ,  Yibin ZENG ,  Penglie ZHANG

IPC: C07D231/14 ,  C07D261/18 ,  C07D317/60 ,  C07D237/24 ,  C07D309/10 ,  C07D275/03 ,  C07D319/12 ,  C07D307/24 ,  C07D207/16 ,  C07D309/06 ,  C07D493/08 ,  C07D295/195 ,  C07D239/28 ,  C07D307/16 ,  C07D265/30 ,  C07D309/28 ,  C07D309/08 ,  C07D211/60 ,  C07D207/22 ,  C07D233/90 ,  C07D317/66 ,  C07D211/62 ,  C07D335/02 ,  C07C311/44 ,  C07D307/68 ,  C07D213/81 ,  C07D471/08

CPC classification number: C07C311/44 ,  C07D207/16 ,  C07D207/22 ,  C07D211/60 ,  C07D211/62 ,  C07D213/81 ,  C07D231/14 ,  C07D233/90 ,  C07D237/24 ,  C07D239/28 ,  C07D261/18 ,  C07D265/30 ,  C07D275/03 ,  C07D295/195 ,  C07D307/16 ,  C07D307/24 ,  C07D307/68 ,  C07D309/06 ,  C07D309/08 ,  C07D309/10 ,  C07D309/28 ,  C07D317/60 ,  C07D317/66 ,  C07D319/12 ,  C07D335/02 ,  C07D471/08 ,  C07D493/08 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/18 ,  C07C2602/42

Abstract: Provided are sulfonamide compounds having formula (I):





or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, R4 and the subscripts n and m have the meanings provided in the specification. The compounds are useful for treating diseases and conditions associated with CXCR6 activity.

公开(公告)号：US11649209B2

公开(公告)日：2023-05-16

申请号：US17841567

申请日：2022-06-15

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Grahame Woollam

IPC: C07D211/62 ,  C07D401/12 ,  A61K31/4545 ,  A61K9/12 ,  A61K9/16 ,  A61K45/06

CPC classification number: C07D211/62 ,  A61K9/124 ,  A61K9/1623 ,  A61K31/4545 ,  A61K45/06 ,  C07D401/12 ,  C07B2200/13

Abstract: The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.

公开(公告)号：US20230143552A1

公开(公告)日：2023-05-11

申请号：US17962346

申请日：2022-10-07

Applicant: The Broad Institute, Inc. ,  Massachusetts Institute of Technology

Inventor： Edward Holson ,  Florence Fevrier Wagner ,  Michel Weiwer ,  Edward Scolnick ,  Michelle Palmer ,  Luka Dordevic ,  Michael C. Lewis ,  Jennifer Q. Pan ,  Yan-Ling Zhang ,  Qihong Xu

IPC: C07D207/12 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/06 ,  C07D413/12 ,  C07D417/12 ,  C07D451/06 ,  C07D471/10 ,  C07D491/048 ,  C07D491/052 ,  C07D491/056 ,  C07D491/107 ,  C07D211/18 ,  C07D211/38 ,  C07D211/42 ,  C07D211/48 ,  C07D211/58 ,  C07D211/62 ,  C07D211/70 ,  C07D211/22 ,  A61P25/18 ,  A61P25/16

CPC classification number: C07D207/12 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/06 ,  C07D413/12 ,  C07D417/12 ,  C07D451/06 ,  C07D471/10 ,  C07D491/048 ,  C07D491/052 ,  C07D491/056 ,  C07D491/107 ,  C07D211/18 ,  C07D211/38 ,  C07D211/42 ,  C07D211/48 ,  C07D211/58 ,  C07D211/62 ,  C07D211/70 ,  C07D211/22 ,  A61P25/18 ,  A61P25/16 ,  C07K14/70571

Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity.

公开(公告)号：US20190202801A1

公开(公告)日：2019-07-04

申请号：US16334335

申请日：2017-09-18

Applicant: ABIDE THERAPEUTICS, INC.

Inventor： Cheryl A. GRICE ,  Daniel J. BUZARD ,  Michael B. SHAGHAFI ,  Olivia D. WEBER

IPC: C07D401/10 ,  C07D403/10 ,  C07D413/10 ,  C07D403/14 ,  C07D405/10 ,  C07D471/06 ,  C07D241/04 ,  A61P23/00 ,  A61P29/00 ,  A61P1/00 ,  A61P25/28

CPC classification number: C07D401/10 ,  A61K45/06 ,  A61P1/00 ,  A61P23/00 ,  A61P25/28 ,  A61P29/00 ,  C07D205/04 ,  C07D207/09 ,  C07D207/16 ,  C07D211/26 ,  C07D211/58 ,  C07D211/60 ,  C07D211/62 ,  C07D231/12 ,  C07D241/04 ,  C07D265/30 ,  C07D295/205 ,  C07D309/08 ,  C07D333/38 ,  C07D333/40 ,  C07D401/04 ,  C07D403/10 ,  C07D403/14 ,  C07D405/10 ,  C07D413/10 ,  C07D471/06 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10

Abstract: Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

公开(公告)号：US20190047957A1

公开(公告)日：2019-02-14

申请号：US16130076

申请日：2018-09-13

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Mathai Mammen ,  YuHua Ji ,  YongQi Mu ,  Craig Husfeld ,  Li Li

IPC: C07D211/62 ,  C07D401/12 ,  A61K45/06 ,  A61K9/16 ,  A61K9/12 ,  A61K31/4545

CPC classification number: C07D211/62 ,  A61K9/124 ,  A61K9/1623 ,  A61K9/1652 ,  A61K31/4545 ,  A61K45/06 ,  C07D401/12

Abstract: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.

公开(公告)号：US20190002414A1

公开(公告)日：2019-01-03

申请号：US15781925

申请日：2016-12-06

Applicant: KISSEI PHARMACEUTICAL CO., LTD.

Inventor： Takashi Miyagi ,  Masahiro Kobayashi ,  Toshihiro Nishimura

IPC: C07D241/04 ,  C07D211/32 ,  C07D401/06 ,  A61P1/08

CPC classification number: C07D241/04 ,  A61K31/451 ,  A61K31/495 ,  A61P1/08 ,  C07D211/32 ,  C07D211/62 ,  C07D401/06

Abstract: A problem of the present invention is to provide a new compound which has NK1 receptor antagonist activity, and thus is useful for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting.A compound represented by the formula (I): wherein W represents a fluorine atom and the like, ring A represents a cycloalkyl and the like, X1 represents CH or N, R represents methyl and the like, Y represents 0 to 2, U1, U2 and U3 each independently represents a single bond and the like, or a pharmaceutically acceptable salt thereof. The compounds of the present invention or pharmaceutically acceptable salts thereof have an excellent NK1 receptor antagonist activity, and thus are also useful as an agent for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting.